Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01943825

Enrollment

Registered

2013-09-17

Start date

2013-11-05

Completion date

2015-11-25

Last updated

2022-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dengue, Dengue Fever, Dengue Hemorrhagic Fever

Keywords

Dengue, Dengue fever, CYD dengue vaccine, IXIARO JE vaccine, Flavivirus

Brief summary

The aim of the study was to evaluate a compressed dosing schedule and the immunologic effects of co-administration of a CYD dengue vaccine with a licensed flavivirus (FV) with Japanese encephalitis (JE) vaccine. Primary Objectives: * To describe and compare the humoral immune response to each of the 4 parental dengue virus serotypes at baseline and 28 days after each CYD dengue vaccine dose. * To describe the persistence of the humoral immune response to each of the 4 parental dengue virus serotypes 6 after CYD dengue vaccine Dose 3, irrespective of whether or not JE vaccine had been previously administered. Secondary Objectives: * To describe the safety profile after each injection of CYD dengue vaccine. * To describe the humoral immune response to each of the 4 parental dengue virus serotypes at baseline and 28 days after each CYD dengue vaccine dose when administered with or after JE virus vaccine in Groups 3 and 4. * To describe the persistence of the humoral immune response to each of the 4 parental dengue virus serotypes at 6 months post-dose 3 in all four groups and at 12 months post-dose 3 in Groups 1 and 3 with the compressed schedule. * To determine the level of viremia on Day (D)0, D3, D5, D7 and D14 following each CYD vaccine dose administered in Groups 1-4. * To describe the JE humoral immune response at baseline and 28 days after each injection of CYD dengue vaccine in Groups 3 and 4.

Detailed description

Study participants were randomly assigned to one of the four groups to receive assigned study vaccine and were evaluated for neutralizing antibody titers; markers of cell-mediated immunity.

Interventions

BIOLOGICALCYD Dengue Vaccine

0.5 mL, Subcutaneous

BIOLOGICALJapanese Encephalitis Vaccine

0.5 mL, Intramuscular

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Aged greater than or equal to (\>=)18 to less than or equal to (\<=) 45 years on the day of inclusion. * Informed consent form had been signed and dated. * Able to attend all scheduled visits and complied with all trial procedures. * Participant was in good health, based on medical history and physical examination.

Exclusion criteria

* Participant was pregnant, or lactating, or of childbearing potential (were considered of non-childbearing potential, a female had to be post- menopausal for at least 1 year, surgically sterile, or used an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination and until at least 4 weeks after the last vaccination). * Participation in the 4 weeks preceding the first trial vaccination, or planned participation during the present trial period, in another clinical trial investigating a vaccine, drug, medical device, or medical procedure. * Receipt or planned receipt of any vaccine, outside the study protocol in the 4 weeks preceded or followed trial vaccinations. (If influenza activity warranted vaccination of healthy young adults, influenza vaccination was encouraged and did not lead to study exclusion). * Any history of FV vaccination, or planned FV vaccination during the trial period. * Previous residence (greater than \[\>\]12 months) in, or travel in the last 30 days to dengue endemic regions. * Receipt of immune globulins, blood or blood-derived products in the 3 months prior to first vaccination or planned use during the study period. * Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceded 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) * Known systemic hypersensitivity to any of the vaccine components (including protamine sulfate), or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances, including dry natural latex. * Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily. * Excessive alcohol consumption or drug addiction. * Chronic illness that, in the opinion of the Investigator, was at a stage where it might interfere with trial conduct or completion. * Identified as an employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employee or the Investigator. * Temporary

Design outcomes

Primary

Measure	Time frame	Description
Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Pre-injection 1, 2 and 3; 28 days post-injection 1, 2 and 3; and 6 months post-injection 3	GMTs of antibodies against each dengue virus serotype (parental strains 1, 2, 3 and 4) were measured by plaque reduction neutralization test (PRNT). The lower limit of quantitation (LLOQ) of the assay was a titer of 10 (1/dilution).
Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Pre-injection 1, 2 and 3; 28 days post-injection 1, 2 and 3; and 6 months post-injection 3	Antibody titers against each dengue virus serotype (parental strains 1, 2, 3 and 4) were measured by PRNT.

Secondary

Measure	Time frame	Description
Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	6 months and 12 months post-injection 3	GMTs of antibodies against each dengue virus serotype (parental strains 1, 2, 3 and 4) were measured by PRNT.
Number of Participants With Detectable Serotype-Specific Vaccine Viremia	3, 5, 7 and 14 days post-injection 1; 3 and 14 days post-injection 2 and 7 days post-injection 3	Viremia was determined by RT PCR using primer/probes specific to each dengue vaccine serotypes.
Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	3, 5, 7 and 14 days post-injection 1, 2 and 3	Viremia was determined by reverse transcriptase (RT) polymerase chain reaction (PCR) using primer/probes specific to a non serotype-specific part of the dengue vaccine.
Number of Participants With Solicited Injection Site Reactions	Within 7 days after any CYD dengue vaccine and/or JE vaccine	A solicited reaction was defined as an adverse reaction observed and reported under the conditions (symptom and onset) pre-listed (i.e., solicited) in the electronic case report form (eCRF) and considered as related to vaccination. Solicited injection site reactions: pain, erythema, and swelling.
Number of Participants With Solicited Systemic Reactions	Within 14 days after any CYD dengue vaccine and/or JE vaccine	A solicited reaction was defined as an adverse reaction observed and reported under the conditions (symptom and onset) pre-listed (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited systemic reactions: fever, headache, malaise, myalgia, and asthenia.
Geometric Means Titers of Antibodies Against Japanese Encephalitis - Groups 3 and 4	Pre-injection 1, and 28 days post-injection 1, 2 and 3	GMTs of antibodies against JE were measured by JE micro neutralization assay. The LLOQ of the assay was a titer of 10 (1/dilution).
Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Pre-injection 1, 2 and 3, and 28 days post-injection 1, 2 and 3	GMTs of antibodies against each dengue virus serotype (parental strains 1, 2, 3 and 4) were measured by PRNT. The LLOQ of the assay was a titer of 10 (1/dilution).

Countries

United States

Participant flow

Recruitment details

Participants were involved in the study from 05 November 2013 to 25 November 2015 in the United States.

Pre-assignment details

A total of 90 participants were enrolled and randomized in the study.

Participants by arm

Arm	Count
CYD Dengue Vaccine: Group 1 Participants received 3 doses of CYD dengue vaccine, one each at 0, 2 and 6 months, respectively.	25
CYD Dengue Vaccine: Group 2 Participants received 3 doses of CYD dengue vaccine, one each at 0, 6 and 12 months, respectively.	15
CYD Dengue and JE Vaccine : Group 3 Participants received 3 doses of CYD dengue vaccine, one each at 0, 2 and 6 months, and 2 doses of JE (IXIARO) vaccine at 0 and 1 months, respectively.	25
CYD Dengue and JE Vaccine: Group 4 Participants received 2 doses of JE (IXIARO) vaccine at 0 and 1 months; and 3 doses of CYD dengue vaccine at 7, 9 and 13 months, respectively.	25
Total	90

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003
Overall Study	Lost to Follow-up	9	3	12	8
Overall Study	Other than specified above	0	1	0	1
Overall Study	Withdrawal by Subject	1	0	3	2

Baseline characteristics

Characteristic	CYD Dengue Vaccine: Group 1	CYD Dengue Vaccine: Group 2	CYD Dengue and JE Vaccine : Group 3	CYD Dengue and JE Vaccine: Group 4	Total
Age, Continuous	31.0 years STANDARD_DEVIATION 6.7	26.8 years STANDARD_DEVIATION 5.6	28.5 years STANDARD_DEVIATION 6.5	30.4 years STANDARD_DEVIATION 6.2	29.4 years STANDARD_DEVIATION 6.4
Sex: Female, Male Female	12 Participants	6 Participants	7 Participants	12 Participants	37 Participants
Sex: Female, Male Male	13 Participants	9 Participants	18 Participants	13 Participants	53 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	0 / 25	0 / 15	0 / 25	0 / 25
other Total, other adverse events	18 / 25	15 / 15	17 / 25	20 / 25
serious Total, serious adverse events	3 / 25	0 / 15	0 / 25	1 / 25

Outcome results

Primary

Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains

GMTs of antibodies against each dengue virus serotype (parental strains 1, 2, 3 and 4) were measured by plaque reduction neutralization test (PRNT). The lower limit of quantitation (LLOQ) of the assay was a titer of 10 (1/dilution).

Time frame: Pre-injection 1, 2 and 3; 28 days post-injection 1, 2 and 3; and 6 months post-injection 3

Population: Analysis was performed on full analysis set which included participants who received at least one injection of CYD dengue vaccine or JE vaccine and had at least one blood sample drawn and valid post-injection serology result. Here, 'Number analyzed' = participants with available data for each specified category.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 1	NA titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 3	120.4 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 1	22.1 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 3	7.1 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 6 months Post-injection 3	19.3 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 2	24.5 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 2	31.0 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 1	NA titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 3	45.5 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 3	22.9 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 3	9.1 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 3	108.9 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 6 months Post-injection 3	5.8 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 6 months Post-injection 3	105.3 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 1	NA titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 2	6.5 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 2	166.6 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 1	9.2 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 2	12.1 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 2	296.2 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 2	19.0 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 3	13.3 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 2	8.5 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 1	425.8 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 3	32.5 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 6 months Post-injection 3	13.9 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 1	6.1 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 1	NA titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 3	124.5 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 1	NA titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 1	NA titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 6 months Post-injection 3	33.9 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 1	669.7 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 1	24.9 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 3	25.5 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 3	9.8 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 1	7.4 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 2	15.4 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 3	6.3 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 3	79.9 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 2	5.4 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 2	40.8 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 2	100.3 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 2	6.2 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 2	9.6 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 3	31.7 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 1	5.5 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 3	89.8 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 6 months Post-injection 3	106.7 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 3	9.9 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 1	NA titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 1	NA titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 6 months Post-injection 3	7.9 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 6 months Post-injection 3	6.6 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 2	10.7 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 2	147.1 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 2	28.5 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 1	NA titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 1	6.8 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 2	6.7 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 2	10.8 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 3	8.3 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 3	12.0 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 6 months Post-injection 3	8.6 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 1	NA titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 1	8.8 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 2	8.8 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 2	17.3 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 3	12.2 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 3	19.3 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 6 months Post-injection 3	10.9 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 1	5.2 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 1	19.7 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 2	23.8 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 3	20.5 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 3	32.2 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 6 months Post-injection 3	19.3 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 1	NA titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 1	177.6 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 2	89.9 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 2	68.0 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 3	47.7 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 3	55.4 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 6 months Post-injection 3	43.8 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 6 months Post-injection 3	21.0 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 3	48.2 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 2	7.2 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 1	NA titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 3	37.4 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 2	61.5 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 6 months Post-injection 3	92.6 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 1	325.4 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 2	44.5 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 1	35.5 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 3	152.5 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 2	300.9 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 1	NA titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 6 months Post-injection 3	7.3 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 1	7.4 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 2	211.3 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 3	12.9 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 3	6.5 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 1	NA titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 3	35.6 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 2	68.8 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 2	49.0 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 3	139.5 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 3	61.8 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 1	49.3 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 1	NA titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 2	10.8 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 6 months Post-injection 3	24.8 titers (1/dilution)

Primary

Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains

Antibody titers against each dengue virus serotype (parental strains 1, 2, 3 and 4) were measured by PRNT.

Time frame: Pre-injection 1, 2 and 3; 28 days post-injection 1, 2 and 3; and 6 months post-injection 3

Population: Analysis was performed on full analysis set. Here, 'Number analyzed' = participants with available data for each specified category.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 1	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 3	16 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 1	15 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 3	3 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: 6 months Post-injection 3	10 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 2	11 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 2	12 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 1	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 3	14 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 3	12 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 3	5 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 3	17 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: 6 months Post-injection 3	2 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: 6 months Post-injection 3	15 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 1	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 2	3 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 2	17 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 1	5 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 2	5 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 2	21 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 2	9 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 3	8 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 2	6 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 1	21 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 3	12 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: 6 months Post-injection 3	7 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 1	3 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 1	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 3	12 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 1	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 1	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: 6 months Post-injection 3	9 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 1	13 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 1	7 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 3	9 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 3	4 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 1	2 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 2	7 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 3	2 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 3	12 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 2	1 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 2	9 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 2	13 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 2	2 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 2	7 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 3	10 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 1	1 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 3	12 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: 6 months Post-injection 3	11 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 3	6 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 1	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 1	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: 6 months Post-injection 3	3 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: 6 months Post-injection 3	2 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 2	5 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 2	13 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 2	10 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 1	0 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 1	3 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 2	2 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 2	5 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 3	3 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 3	5 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: 6 months Post-injection 3	2 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 1	0 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 1	4 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 2	4 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 2	7 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 3	7 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 3	9 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: 6 months Post-injection 3	4 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 1	1 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 1	10 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 2	10 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 3	9 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 3	9 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: 6 months Post-injection 3	6 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 1	0 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 1	16 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 2	11 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 2	11 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 3	11 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 3	11 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: 6 months Post-injection 3	7 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: 6 months Post-injection 3	9 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 3	15 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 2	4 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 1	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 3	13 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 2	16 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: 6 months Post-injection 3	14 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 1	18 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 2	15 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: 28 days Post-injection 1	16 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 3	16 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 2	18 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 2: Pre-injection 1	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: 6 months Post-injection 3	4 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 1	6 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: 28 days Post-injection 2	18 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 3	9 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 3	3 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: Pre-injection 1	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 3	12 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 2	16 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 2	14 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 4: Pre-injection 3	16 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 3	16 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: 28 days Post-injection 1	16 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: Pre-injection 1	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 1: 28 days Post-injection 2	8 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains	Serotype 3: 6 months Post-injection 3	10 Participants

Secondary

Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains

GMTs of antibodies against each dengue virus serotype (parental strains 1, 2, 3 and 4) were measured by PRNT.

Time frame: 6 months and 12 months post-injection 3

Population: Analysis was performed on full analysis set. Here, 'Number analyzed' = participants with available data for each specified category. Data was not planned to be collected and analyzed for Groups 2 and 4 for 12 months post-injection 3 time point.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 6 months Post-injection 3	19.3 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 6 months Post-injection 3	5.8 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 6 months Post-injection 3	105.3 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 12 months Post-injection 3	144.8 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 12 months Post-injection 3	18.3 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 6 months Post-injection 3	13.9 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 12 months Post-injection 3	11.5 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 12 months Post-injection 3	5.3 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 6 months Post-injection 3	7.9 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 6 months Post-injection 3	6.6 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 6 months Post-injection 3	33.9 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 6 months Post-injection 3	106.7 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 6 months Post-injection 3	19.3 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 12 months Post-injection 3	23.9 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 6 months Post-injection 3	43.8 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 6 months Post-injection 3	10.9 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 12 months Post-injection 3	7.6 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 12 months Post-injection 3	16.2 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 6 months Post-injection 3	8.6 titers (1/dilution)
CYD Dengue and JE Vaccine : Group 3	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 12 months Post-injection 3	7.8 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 4: 6 months Post-injection 3	92.6 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 2: 6 months Post-injection 3	21.0 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 3: 6 months Post-injection 3	24.8 titers (1/dilution)
CYD Dengue and JE Vaccine: Group 4	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains	Serotype 1: 6 months Post-injection 3	7.3 titers (1/dilution)

Secondary

Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4

GMTs of antibodies against each dengue virus serotype (parental strains 1, 2, 3 and 4) were measured by PRNT. The LLOQ of the assay was a titer of 10 (1/dilution).

Time frame: Pre-injection 1, 2 and 3, and 28 days post-injection 1, 2 and 3

Population: Analysis was performed on full analysis set. Here, 'Number analyzed' = participants with available data for each specified category.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 2: Pre-injection 1	NA titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 1: 28 days Post-injection 1	6.8 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 1: Pre-injection 2	6.7 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 1: 28 days Post-injection 2	10.8 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 1: Pre-injection 3	8.3 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 1: 28 days Post-injection 3	12.0 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 1: Pre-injection 1	NA titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 2: 28 days Post-injection 1	8.8 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 2: Pre-injection 2	8.8 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 2: 28 days Post-injection 2	17.3 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 2: Pre-injection 3	12.2 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 2: 28 days Post-injection 3	19.3 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 3: Pre-injection 1	5.2 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 3: 28 days Post-injection 1	19.7 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 3: Pre-injection 2	23.8 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 3: 28 days Post-injection 2	28.5 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 3: Pre-injection 3	20.5 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 3: 28 days Post-injection 3	32.2 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 4: Pre-injection 1	NA titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 4: 28 days Post-injection 1	177.6 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 4: Pre-injection 2	89.9 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 4: 28 days Post-injection 2	68.0 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 4: Pre-injection 3	47.7 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 4: 28 days Post-injection 3	55.4 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 4: Pre-injection 3	139.5 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 1: Pre-injection 1	NA titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 3: Pre-injection 1	NA titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 1: 28 days Post-injection 1	7.4 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 4: Pre-injection 1	NA titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 1: Pre-injection 2	7.2 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 3: 28 days Post-injection 1	49.3 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 1: 28 days Post-injection 2	10.8 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 4: 28 days Post-injection 2	211.3 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 1: Pre-injection 3	6.5 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 3: Pre-injection 2	49.0 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 1: 28 days Post-injection 3	12.9 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 4: 28 days Post-injection 1	325.4 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 2: Pre-injection 1	NA titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 3: 28 days Post-injection 2	68.8 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 2: 28 days Post-injection 1	35.5 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 4: 28 days Post-injection 3	152.5 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 2: Pre-injection 2	44.5 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 3: Pre-injection 3	35.6 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 2: 28 days Post-injection 2	61.5 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 4: Pre-injection 2	300.9 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 2: Pre-injection 3	37.4 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 3: 28 days Post-injection 3	61.8 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4	Serotype 2: 28 days Post-injection 3	48.2 titers (1/dilution)

Secondary

Geometric Means Titers of Antibodies Against Japanese Encephalitis - Groups 3 and 4

GMTs of antibodies against JE were measured by JE micro neutralization assay. The LLOQ of the assay was a titer of 10 (1/dilution).

Time frame: Pre-injection 1, and 28 days post-injection 1, 2 and 3

Population: Analysis was performed on full analysis set. Here, 'Number analyzed' = participants with available data for each specified category.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Japanese Encephalitis - Groups 3 and 4	Pre-injection 1	NA titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Japanese Encephalitis - Groups 3 and 4	28 days Post-injection 1	132.3 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Japanese Encephalitis - Groups 3 and 4	28 days Post-injection 2	382.7 titers (1/dilution)
CYD Dengue Vaccine: Group 1	Geometric Means Titers of Antibodies Against Japanese Encephalitis - Groups 3 and 4	28 days Post-injection 3	82.3 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Japanese Encephalitis - Groups 3 and 4	28 days Post-injection 3	157.4 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Japanese Encephalitis - Groups 3 and 4	Pre-injection 1	22.9 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Japanese Encephalitis - Groups 3 and 4	28 days Post-injection 2	501.8 titers (1/dilution)
CYD Dengue Vaccine: Group 2	Geometric Means Titers of Antibodies Against Japanese Encephalitis - Groups 3 and 4	28 days Post-injection 1	620.9 titers (1/dilution)

Secondary

Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia

Viremia was determined by reverse transcriptase (RT) polymerase chain reaction (PCR) using primer/probes specific to a non serotype-specific part of the dengue vaccine.

Time frame: 3, 5, 7 and 14 days post-injection 1, 2 and 3

Population: Analysis was performed on full analysis set. Here, 'Number analyzed' = participants with available data for each specified category.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	5 days Post-Injection 3	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	14 days Post-Injection 3	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	14 days Post-Injection 2	1 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	3 days Post-Injection 1	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	3 days Post-Injection 3	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	7 days Post-Injection 1	16 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	14 days Post-Injection 1	12 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	5 days Post-Injection 1	7 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	7 days Post-Injection 3	1 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	3 days Post-Injection 2	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	5 days Post-Injection 2	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	7 days Post-Injection 2	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	5 days Post-Injection 1	5 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	7 days Post-Injection 2	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	14 days Post-Injection 1	4 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	3 days Post-Injection 3	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	5 days Post-Injection 3	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	14 days Post-Injection 2	1 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	3 days Post-Injection 1	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	5 days Post-Injection 2	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	3 days Post-Injection 2	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	7 days Post-Injection 1	9 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	14 days Post-Injection 3	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	7 days Post-Injection 3	0 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	14 days Post-Injection 2	0 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	3 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	5 days Post-Injection 1	1 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	7 days Post-Injection 1	8 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	14 days Post-Injection 1	3 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	3 days Post-Injection 2	0 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	5 days Post-Injection 2	0 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	7 days Post-Injection 2	0 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	3 days Post-Injection 3	0 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	5 days Post-Injection 3	0 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	7 days Post-Injection 3	0 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	14 days Post-Injection 3	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	5 days Post-Injection 2	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	3 days Post-Injection 2	1 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	3 days Post-Injection 1	1 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	5 days Post-Injection 3	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	14 days Post-Injection 1	6 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	7 days Post-Injection 1	9 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	14 days Post-Injection 3	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	7 days Post-Injection 3	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	14 days Post-Injection 2	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	7 days Post-Injection 2	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	5 days Post-Injection 1	3 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia	3 days Post-Injection 3	0 Participants

Secondary

Number of Participants With Detectable Serotype-Specific Vaccine Viremia

Viremia was determined by RT PCR using primer/probes specific to each dengue vaccine serotypes.

Time frame: 3, 5, 7 and 14 days post-injection 1; 3 and 14 days post-injection 2 and 7 days post-injection 3

Population: Analysis was performed on full analysis set. Here, 'Number analyzed' = participants with available data for each specified category.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 3: 14 days Post-Injection 2	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 3: 7 days Post-Injection 3	1 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 4: 5 days Post-Injection 1	6 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 1: 7 days Post-Injection 3	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 4: 7 days Post-Injection 1	13 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 1: 7 days Post-Injection 1	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 4: 14 days Post-Injection 1	8 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 2: 5 days Post-Injection 1	2 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 4: 14 days Post-Injection 2	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 4: 7 days Post-Injection 3	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 2: 7 days Post-Injection 1	2 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 2: 14 days Post-Injection 1	1 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 1: 14 days Post-Injection 1	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 2: 14 days Post-Injection 2	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 2: 7 days Post-Injection 3	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 3: 5 days Post-Injection 1	1 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 3: 7 days Post-Injection 1	5 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 3: 14 days Post-Injection 1	1 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 1: 5 days Post-Injection 1	0 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 1: 14 days Post-Injection 2	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 2: 14 days Post-Injection 2	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 4: 7 days Post-Injection 1	7 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 2: 14 days Post-Injection 1	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 1: 7 days Post-Injection 1	1 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 1: 14 days Post-Injection 1	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 4: 14 days Post-Injection 1	2 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 3: 14 days Post-Injection 2	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 1: 5 days Post-Injection 1	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 2: 5 days Post-Injection 1	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 3: 5 days Post-Injection 1	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 4: 14 days Post-Injection 2	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 1: 14 days Post-Injection 2	0 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 3: 7 days Post-Injection 1	2 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 4: 5 days Post-Injection 1	3 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 2: 7 days Post-Injection 1	1 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 3: 14 days Post-Injection 1	1 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 3: 5 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 1: 14 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 2: 7 days Post-Injection 1	1 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 1: 7 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 2: 14 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 4: 5 days Post-Injection 1	1 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 3: 7 days Post-Injection 1	1 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 4: 7 days Post-Injection 1	5 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 1: 5 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 4: 14 days Post-Injection 1	2 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 3: 14 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 2: 5 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 4: 7 days Post-Injection 1	7 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 1: 5 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 1: 7 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 1: 14 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 1: 3 days Post-Injection 2	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 2: 3 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 2: 5 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 2: 7 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 2: 14 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 2: 3 days Post-Injection 2	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 3: 3 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 3: 5 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 3: 7 days Post-Injection 1	4 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 3: 14 days Post-Injection 1	1 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 3: 3 days Post-Injection 2	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 4: 3 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 4: 5 days Post-Injection 1	2 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 1: 3 days Post-Injection 1	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 4: 14 days Post-Injection 1	4 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Detectable Serotype-Specific Vaccine Viremia	Serotype 4: 3 days Post-Injection 2	0 Participants

Secondary

Number of Participants With Solicited Injection Site Reactions

A solicited reaction was defined as an adverse reaction observed and reported under the conditions (symptom and onset) pre-listed (i.e., solicited) in the electronic case report form (eCRF) and considered as related to vaccination. Solicited injection site reactions: pain, erythema, and swelling.

Time frame: Within 7 days after any CYD dengue vaccine and/or JE vaccine

Population: Analysis was performed on safety analysis set. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
CYD Dengue Vaccine: Group 1	Number of Participants With Solicited Injection Site Reactions	Injection site Pain	7 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Solicited Injection Site Reactions	Injection site Swelling	3 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Solicited Injection Site Reactions	Injection site Erythema	7 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Solicited Injection Site Reactions	Injection site Pain	6 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Solicited Injection Site Reactions	Injection site Swelling	2 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Solicited Injection Site Reactions	Injection site Erythema	4 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Solicited Injection Site Reactions	Injection site Erythema	2 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Solicited Injection Site Reactions	Injection site Pain	3 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Solicited Injection Site Reactions	Injection site Swelling	0 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Solicited Injection Site Reactions	Injection site Pain	6 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Solicited Injection Site Reactions	Injection site Swelling	1 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Solicited Injection Site Reactions	Injection site Erythema	2 Participants

Secondary

Number of Participants With Solicited Systemic Reactions

A solicited reaction was defined as an adverse reaction observed and reported under the conditions (symptom and onset) pre-listed (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited systemic reactions: fever, headache, malaise, myalgia, and asthenia.

Time frame: Within 14 days after any CYD dengue vaccine and/or JE vaccine

Population: Analysis was performed on safety analysis set. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
CYD Dengue Vaccine: Group 1	Number of Participants With Solicited Systemic Reactions	Myalgia	8 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Solicited Systemic Reactions	Headache	10 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Solicited Systemic Reactions	Asthenia	6 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Solicited Systemic Reactions	Malaise	9 Participants
CYD Dengue Vaccine: Group 1	Number of Participants With Solicited Systemic Reactions	Fever	2 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Solicited Systemic Reactions	Malaise	10 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Solicited Systemic Reactions	Myalgia	6 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Solicited Systemic Reactions	Asthenia	7 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Solicited Systemic Reactions	Headache	11 Participants
CYD Dengue Vaccine: Group 2	Number of Participants With Solicited Systemic Reactions	Fever	2 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Solicited Systemic Reactions	Malaise	11 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Solicited Systemic Reactions	Fever	3 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Solicited Systemic Reactions	Headache	12 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Solicited Systemic Reactions	Myalgia	10 Participants
CYD Dengue and JE Vaccine : Group 3	Number of Participants With Solicited Systemic Reactions	Asthenia	7 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Solicited Systemic Reactions	Myalgia	7 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Solicited Systemic Reactions	Headache	11 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Solicited Systemic Reactions	Fever	1 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Solicited Systemic Reactions	Malaise	6 Participants
CYD Dengue and JE Vaccine: Group 4	Number of Participants With Solicited Systemic Reactions	Asthenia	3 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains

Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains

Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains

Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4

Geometric Means Titers of Antibodies Against Japanese Encephalitis - Groups 3 and 4

Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia

Number of Participants With Detectable Serotype-Specific Vaccine Viremia

Number of Participants With Solicited Injection Site Reactions

Number of Participants With Solicited Systemic Reactions